Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: A clinical phase I/II study

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Baumann, Ulrich ^a   Göcke, Kerstin ^a   Gewecke, Britta ^a   Freihorst, Joachim ^a,b   von Specht, Bernd U ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Pediatric Hospital   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPROTEIN; OUTER MEMBRANE LIPOPROTEIN I, BACTERIA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; EVALUATION; FEASIBILITY STUDY; GEL; GENETICS; GRAM NEGATIVE INFECTION; HUMAN; IMMUNIZATION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; LUNG LAVAGE; METABOLISM; METHODOLOGY; MICROBIOLOGY; MUCOSAL IMMUNITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSEUDOMONAS AERUGINOSA; REFERENCE VALUE; RESPIRATORY TRACT MUCOSA; SPUTUM; TIME; VACCINATION;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; BRONCHOALVEOLAR LAVAGE FLUID; FEASIBILITY STUDIES; GELS; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; LIPOPROTEINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES; RESPIRATORY MUCOSA; SPUTUM; TIME FACTORS; VACCINATION;

EID: 34548797131     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-57     Document Type: Article

References (24)

1. Doring G, Dorner F. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. BehringInstMitt 1997, 338-344. 9382758.
2. Lang AB, Rudeberg A, Schoni MH, Que JU, Furer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. PediatrInfectDisJ 2004, 23:504-510. 15194830.
3. Pier G. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. Expert Rev Vaccines 2005, 4:645-656. 10.1586/14760584.4.5.645, 16221066.
4. Baumann U, Mansouri E, von Specht BU. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections. Vaccine 2004, 22:840-847. 10.1016/j.vaccine.2003.11.029, 15040936.
5. Knapp B, Hundt E, Lenz U, Hungerer KD, Gabelsberger J, Domdey H, Mansouri E, Li Y, von Specht BU. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine 1999, 17:1663-1666. 10.1016/S0264-410X(98)00420-4, 10194820.
6. Mansouri E, Gabelsberger J, Knapp B, Hundt E, Lenz U, Hungerer KD, Gilleland HE, Staczek J, Domdey H, von Specht BU. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. InfectImmun 1999, 67:1461-1470. 10024596.
7. Mansouri E, Blome-Eberwein S, Gabelsberger J, Germann G, von Specht BU. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients. FEMS ImmunolMed Microbiol 2003, 37:161-166.
8. Kunkel EJ, Butcher EC. Plasma-cell homing. NatRevImmunol 2003, 3:822-829. 14523388.
9. Rudin A, Riise GC, Holmgren J. Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. InfectImmun 1999, 67:2884-2890. 10338495.
10. Larbig M, Mansouri E, Freihorst J, Tummler B, Kohler G, Domdey H, Knapp B, Hungerer KD, Hundt E, Gabelsberger J, von Specht BU. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 2001, 19:2291-2297. 10.1016/S0264-410X(00)00550-8, 11257350.
11. Gocke K, Baumann U, Hagemann H, Gabelsberger J, Hahn H, Freihorst J, von Specht BU. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule. FEMS ImmunolMedMicrobiol 2003, 37:167-171.
12. Doring G, Pfeiffer C, Weber U, Mohr-Pennert A, Dorner F. Parenteral application of a Pseudomonas aeruginosa flagella vaccine elicits specific anti-flagella antibodies in the airways of healthy individuals. Am J Respir Crit Care Med 1995, 151:983-985.
13. Ho SA, Ball R, Morrison LJ, Brownlee KG, Conway SP. Clinical value of obtaining sputum and cough swab samples following inhaled hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 2004, 38:82-87. 10.1002/ppul.20035, 15170878.
14. Rutgers SR, Timens W, Kaufmann HF, van der Mark TW, Koeter GH, Postma DS. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. EurRespirJ 2000, 15:109-115. 10678630.
15. Herremans TM, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. JImmunol 1999, 162:5011-5018. 10202050.
16. Haslam PL, Baughman RP. Report of ERS Task Force: guidelines for measurement of acellular components and standardization of BAL. Eur Respir J 1999, 14:245-248. 10.1034/j.1399-3003.1999.14b01.x, 10515395.
17. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanovic R, Maestrelli P, Sterk PJ. Sputum induction. Eur Respir J Suppl 2002, 37:3s-8s. 10.1183/09031936.02.00000302, 12361361.
18. Ratjen F, Bredendiek M, Brendel M, Meltzer J, Costabel U. Differential cytology of bronchoalveolar lavage fluid in normal children. Eur Respir J 1994, 7:1865-1870. 10.1183/09031936.94.07101865, 7828697.
19. Pilette C, Ouadriri Y, Godding V, Vaerman JP, Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. EurRespirJ 2001, 18:571-588.
20. Keatings VM, Evans DJ, O'Connor BJ, Barnes PJ. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax 1997, 52:372-374.
21. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2006,
22. Potts SB, Roggli VL, Spock A. Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. Pediatr Pathol Lab Med 1995, 15:707-721.
23. Jones PD, Hankin R, Simpson J, Gibson PG, Henry RL. The tolerability, safety, and success of sputum induction and combined hypertonic saline challenge in children. AmJRespirCrit Care Med 2001, 164:1146-1149.
24. Doring G, Meisner C, Stern M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A 2007, 104:11020-11025. 10.1073/pnas.0702403104, 17585011.